<div id="readability-page-1"><p>Citi analyst Samantha Semenkow has maintained their bullish  stance on <span>BEAM</span> stock, giving a Buy rating yesterday.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Samantha Semenkow has given his Buy rating due to a combination of factors that underscore Beam Therapeutics’ strong clinical and regulatory momentum. The company is moving efficiently toward a pivotal, open-label cohort for BEAM-302 in AATD in the second half of 2026, backed by recent Phase 1/2 data that show a robust efficacy profile with AAT levels in a protective range. </p> <p>Moreover, Beam is progressing risto-cel toward a planned BLA filing by year-end 2026, supported by data highlighted in a NEJM publication that point to meaningful advantages in efficacy, engraftment speed, hospitalization time, and manufacturing. Additional upcoming milestones, including initial BEAM-301 data in GSD1a and an IND for BEAM-304 in PKU, together with updated financial modeling and an unchanged $68 price target, reinforce her positive risk/reward view and support the Buy recommendation.</p> <p>In another report released yesterday, Bernstein also assigned a Buy rating to the stock with a $39.00 price target.</p></div>

BEAM

SBIO

IBBQ

LABU

<p>Citi analyst Samantha Semenkow has reaffirmed a Buy rating for Beam Therapeutics (BEAM) stock, maintaining a $68 price target. The positive outlook is based on the company's strong clinical momentum, including progress towards a pivotal cohort for BEAM-302 and a planned BLA filing for risto-cel by 2026. Recent data supports Beam's efficacy and advantages in treatment outcomes. Bernstein also assigned a Buy rating with a $39 price target, further supporting the positive sentiment around the stock.</p>

- Citigroup analyst Samantha Semenkow maintains a bullish rating on BEAM stock, giving it a buy recommendation.  
- The positive outlook stems from Beam Therapeutics' strong clinical and regulatory momentum, particularly with the BEAM-302 trial and upcoming submissions for risto-cel.  
- Bernstein also rated the stock as a buy, with a target price of $39.00, reinforcing confidence in the company's growth potential.

Tip Ranks

Beam Therapeutics

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Citigroup

AllianceBernstein

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged